Program
Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Charles River Laboratories Intl (NY: CRL )

182.48 +1.52 (+0.84%)
Official Closing Price Updated: 4:10 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Charles River Laboratories Intl

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Thermo Fisher Stock Lights Up The Board, Soars 40% In 5 Months
Thermo Fisher stock has risen more than 40% since October. Additionally, it's closed higher nine of the past 11 trading sessions. 
Via Investor's Business Daily
Charles River and Wheeler Bio Complete Agreement to Accelerate the Journey from Discovery and CMC Development to Manufacturing
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells
From Charles River Laboratories International, Inc.
Via Business Wire
The Next Johnson & Johnson? 3 Healthcare Stocks That Investors Shouldn’t Ignore.
Looking for the next generational winner in healthcare stocks? These are three of the top prospects today. 
Via InvestorPlace
Forecasting The Future: 4 Analyst Projections For Charles River
Via Benzinga
Earnings Scheduled For February 14, 2024
Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is projected to report quarterly earnings at $1.65 per share on revenue of $24.62 billion. 
Via Benzinga
9 Analysts Have This to Say About Charles River
Via Benzinga
Stocks Rebound As Investor Focus Shifts To Earnings, Bitcoin Tops $1 Trillion Value: What's Driving Markets Wednesday?
The U.S. stock market attempted a rebound following Tuesday’s declines, which were sparked by a higher-than-expected inflation report in January, as investors refocused on corporate earnings. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Charles River Laboratories Stock Surges On Upbeat Annual Outlook, But This Analyst Is Concerned
Charles River Laboratories Q4 2023 revenue: $1.01 billion, down 7.9% YoY, beating consensus. Analysts note mixed Q4 performance, keeping Outperform rating. 
Via Benzinga
Charles River Laboratories International Posts Upbeat Results, Joins Robinhood, Zillow, Tower Semiconductor And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining more than 100 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Expert Ratings for Charles River
Via Benzinga
8 Analysts Have This to Say About Charles River
Via Benzinga
Why Sony Shares Are Trading Lower By Around 6%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Sony Group Corporation (NYSE: SONY) fell during Wednesday’s session after the company reported third-quarter financial results and revised guidance above estimates and shared plans to list... 
Via Benzinga
Charles River Introduces the First Rapid Animal-Free Bacterial Endotoxin Test
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Adds Reshema Kemps-Polanco to Board of Directors
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Schedules Fourth-Quarter 2023 Earnings and 2024 Guidance Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
Ten Big Losers To Start The Year. Tesla Isn't The Worst.
Enphase Energy remains out of phase with the stock market. 
Via Investor's Business Daily
Charles River Launches Rep/Cap Plasmids to Streamline Adeno-Associated Viral Vector Manufacturing
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Finalizes Agreement with CELLphenomics, Expanding 3D In Vitro Services for Cancer Therapy Drug Screening
From Charles River Laboratories International, Inc.
Via Business Wire
Investing in the Aging Population: 3 Healthcare Stocks to Watch
America is becoming a much older country on average. These three healthcare stocks are ideally positioned for this demographic shift. 
Via InvestorPlace
Charles River and Genetic Cures for Kids Announce Gene Therapy Manufacturing Collaboration
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories to Present at Evercore ISI Investor Conference
From Charles River Laboratories International, Inc.
Via Business Wire
The 3 Most Undervalued Tech Stocks to Buy Now: November 2023
Growth stocks are rallying but there are still bargains to be found. These three top tech picks can reward long-term investors. 
Via InvestorPlace
Charles River Introduces CliniPrime Cryopreserved Leukopaks, Expanding Suite of GMP-Compliant Cellular Products
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Aitia Enter Strategic Agreement to Utilize Logica in Discovery Programs for Neurodegenerative Diseases and Oncology
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories’ Industry Experts to Present Advanced Modalities at Neuroscience 2023
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Labs Q3 Revenue Jumps 4% Despite Softer Client Spending, Narrows Outlook
Charles River Laboratories International Inc (NYSE: CRL) reported third-quarter (Q3) sales of $1.03 billion, an increase of 3.8% Y/Y, beating the  
Via Benzinga
Charles River Laboratories Announces Third-Quarter 2023 Results
From Charles River Laboratories International, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.